02.22.24
Supplementation with a whole fruit cranberry powder manufactured by private label company PharmaLinea led to significantly reduced risk of urinary tract infection (UTI) recurrence compared to treatment with antibiotics alone, according to a newly published study.
The study included 98 female patients between the ages of 18 and 80 with acute active cystitis, which was confirmed by a positive bacteriological urine test. For 12 weeks, patients either took the cranberry powder sachets in conjunction with standard antibiotic treatment, or the antibiotics alone.
In total, 77.6% of patients in the control group experienced a relapse, while only 19.2% of the study group saw a relapse, which represents a four-times reduction in risk. Similarly, there was a 3.7-times lower rate of recurrence of UTIs in the treatment group compared to control. The treatment group also had 20% greater scores in a self-reported quality of life assessment. The compliance rate in the study population was 98%.
“Already a commercial success, the product has secured the number oen spot in two European markets and has been launched by brand owners in multiple markets across Europe, Asia, LATAM, and the Middle East. The new clinical data is bound to only increase the opportunity,” said Jernej Klopčič, PharmaLinea's Business Development Director.
“It is a great example of how nutraceutical solutions can not only prevent or help with recovery but also complement traditional pharmaceutical products to improve treatment. Of course, there are other UTI supplements on the market but few have clinically supported efficacy and are thus relatively useless to urologists. Our UTI products are a unique combination of our own proprietary whole-fruit cranberry ingredient Qcran, a clinically relevant dose of D-mannose, and microencapsulated vitamin D3, packed in a single sachet. Qcran is one of the few if not only cranberry ingredient that is 100% whole fruit, without any sort of extraction taking place. This is achieved through a unique cold fusion production process. The resulting product retains all the beneficial properties of cranberries, including a very high fiber content, higher than any other cranberry ingredient we’ve tested. This results in the active ingredient PAC being protected, released into the bloodstream in a sustained manner, and ultimately having higher efficacy. Clinical trials are relatively rare for finished products in supplements and even more so for private label products. The investment in extensive scientific support of the product was made to empower both women and doctors with an important tool for prevention and care,” said Matevž Ambrožič, marketing director of PharmaLinea.
The study included 98 female patients between the ages of 18 and 80 with acute active cystitis, which was confirmed by a positive bacteriological urine test. For 12 weeks, patients either took the cranberry powder sachets in conjunction with standard antibiotic treatment, or the antibiotics alone.
In total, 77.6% of patients in the control group experienced a relapse, while only 19.2% of the study group saw a relapse, which represents a four-times reduction in risk. Similarly, there was a 3.7-times lower rate of recurrence of UTIs in the treatment group compared to control. The treatment group also had 20% greater scores in a self-reported quality of life assessment. The compliance rate in the study population was 98%.
“Already a commercial success, the product has secured the number oen spot in two European markets and has been launched by brand owners in multiple markets across Europe, Asia, LATAM, and the Middle East. The new clinical data is bound to only increase the opportunity,” said Jernej Klopčič, PharmaLinea's Business Development Director.
“It is a great example of how nutraceutical solutions can not only prevent or help with recovery but also complement traditional pharmaceutical products to improve treatment. Of course, there are other UTI supplements on the market but few have clinically supported efficacy and are thus relatively useless to urologists. Our UTI products are a unique combination of our own proprietary whole-fruit cranberry ingredient Qcran, a clinically relevant dose of D-mannose, and microencapsulated vitamin D3, packed in a single sachet. Qcran is one of the few if not only cranberry ingredient that is 100% whole fruit, without any sort of extraction taking place. This is achieved through a unique cold fusion production process. The resulting product retains all the beneficial properties of cranberries, including a very high fiber content, higher than any other cranberry ingredient we’ve tested. This results in the active ingredient PAC being protected, released into the bloodstream in a sustained manner, and ultimately having higher efficacy. Clinical trials are relatively rare for finished products in supplements and even more so for private label products. The investment in extensive scientific support of the product was made to empower both women and doctors with an important tool for prevention and care,” said Matevž Ambrožič, marketing director of PharmaLinea.
